Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection

Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus... Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9l2nY+zyylnl33NGMK6MRsx on 10/02/2020 REVIEW URRENT Challenges and opportunities for hepatitis B cure PINION in the setting of HIV–hepatitis B virus co-infection a b,c Jennifer Audsley and Joe Sasadeusz Purpose of review To examine issues specific to HIV–HBV co-infection that are relevant to the search for and achieving hepatitis B cure in this the setting Recent findings In HIV–HBV co-infection, high rates of hepatitis B surface antigen (HBsAg) loss early after initiation of HBV- active antiretroviral therapy (ART) have previously been reported. Between 2012 and 2016, HBsAg loss from 2.8 to 23% was reported in numerous studies, including those already on suppressive HBV-active ART. Data published in 2018–2019 show that these rates have remained fairly stable (3.0–13.9%). However, it appears that higher HBsAg loss on starting HBV-active ART in co-infection falls within a few years to levels similar to that observed in long-term treated HBV mono-infection. Immune reconstitution and CD4þ T-cell recovery are likely to play a role in high HBsAg loss rates seen in early treated co-infection, although the mechanisms driving this are yet to be fully elucidated. Summary High rates of HBsAg loss early after HBV-active ART initiation is unique to HIV–HBV co-infection, making http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection

Loading next page...
 
/lp/wolters-kluwer-health/challenges-and-opportunities-for-hepatitis-b-cure-in-the-setting-of-G3SCij6JhF

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000624
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9l2nY+zyylnl33NGMK6MRsx on 10/02/2020 REVIEW URRENT Challenges and opportunities for hepatitis B cure PINION in the setting of HIV–hepatitis B virus co-infection a b,c Jennifer Audsley and Joe Sasadeusz Purpose of review To examine issues specific to HIV–HBV co-infection that are relevant to the search for and achieving hepatitis B cure in this the setting Recent findings In HIV–HBV co-infection, high rates of hepatitis B surface antigen (HBsAg) loss early after initiation of HBV- active antiretroviral therapy (ART) have previously been reported. Between 2012 and 2016, HBsAg loss from 2.8 to 23% was reported in numerous studies, including those already on suppressive HBV-active ART. Data published in 2018–2019 show that these rates have remained fairly stable (3.0–13.9%). However, it appears that higher HBsAg loss on starting HBV-active ART in co-infection falls within a few years to levels similar to that observed in long-term treated HBV mono-infection. Immune reconstitution and CD4þ T-cell recovery are likely to play a role in high HBsAg loss rates seen in early treated co-infection, although the mechanisms driving this are yet to be fully elucidated. Summary High rates of HBsAg loss early after HBV-active ART initiation is unique to HIV–HBV co-infection, making

Journal

Current Opinion in HIV & AIDSWolters Kluwer Health

Published: May 1, 2020

There are no references for this article.